All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
The present invention relates generally to treatment of heart disease, and more particularly, implantable valve prostheses and treatments for heart valve diseases.
Referring to
Blood flow between the heart chambers is regulated by the valves. On the left side of the heart, the mitral valve 4 is located between the left atrium 25 and the left ventricle 26 and the aortic valve 9 is located between the left ventricle 26 and the aorta 1. On the right side of the heart 2, the pulmonary valve 3 is located between the right ventricle 6 and the pulmonary artery 7 and the tricuspid valve 8 is located between the right ventricle 6 and the right atrium 5.
All four of heart valves are passive one-way valves with “leaflets” which open and close in response to differential pressures. For example, in a healthy heart during systole the left ventricle 26 contracts and pushes blood out the aortic valve 9. In turn, the pressure in the left ventricle 26 causes the mitral valve 4 to close thereby preventing blood from going back into the left atrium 25 during systole.
A significant population will acquire valve disease in their lifetime. Congenital heart disease is also a significant problem. Patients with valvular disease have abnormal anatomy and/or function of at least one valve. Congenital valve abnormalities may be tolerated and/or treated palliatively for some years before developing into a life-threatening problem in later years. However, congenital heart disease may present life-threatening risk without notice. Patients may acquire valvular disease from rheumatic fever, heart failure, degenerative leaflet tissue, bacterial infection, and more.
Valvular disease may be caused by several factors as shown in
While medications may be used to treat the disease, in many cases the defective valve may need to be repaired or replaced at some point during the patient's lifetime. The native valve can be replaced with a mechanical valve or tissue valve. Mechanical valves have a disc or other member which opens and closes. Although mechanical valves are formed of biocompatible materials, they carry an increased risk of clotting. Thus, patients usually need to take anticoagulants for the remainder of their lives, which presents additional complications. Tissue valves can be formed of human or animal tissue, as well as polymeric materials. Tissue valves, unlike mechanical valves, do not typically require long-term use of anti-coagulants, but because they are formed of a living tissue they are not as widely available nor do they last as long as mechanical valves. Common tissue valves include porcine aortic valves mounted within a stent-like structure.
More recently there has been increased interest in less invasive procedures for implantation of prosthetic valves. One type of percutaneous procedure involves using a catheter to place a prosthetic valve inside of a diseased or injured heart valve.
Existing percutaneous procedures for valve repair still face many challenges. These challenges have limited the adoption of transcatheter procedures to certain patient populations and anatomies. Thus far, transcatheter devices are largely focused on aortic valve procedures and the sickest patient populations who may not be able to tolerate surgery. There is a continuing need for improved transcatheter devices which meet or exceed the performance and safety of surgical valves. Percutaneous valve replacement has also been limited to aortic valve procedures. While a large segment of the population suffers from tricuspid and mitral valve disease, the anatomy and function of these valves present challenges to transcatheter replacement. The aortic valve can be accessed via the femoral artery whereas the mitral valve, for example, typically requires a transseptal approach. The mitral valve anatomy presents more complexities to transcatheter procedures than the aortic valve. For example, as shown in
It would therefore be desirable to provide a less invasive procedure for repair and replacement of heart valves, including the mitral valve, quicker surgical methods, a variety of different valve assemblies to accommodate the requirements of different patients, and/or prosthetic valves that can accommodate a variety of individual patients. Not necessarily all such aspects or advantages are achieved by any particular embodiment. Thus, various embodiments may be carried out in a manner that achieves or optimizes one advantage or group of advantages taught herein without necessarily achieving other aspects or advantages as may also be taught or suggested herein.
The present disclosure relates to prosthetic cardiac devices, and in some embodiments, prosthetic heart valves such as catheter-based mitral valves.
In a first aspect, a heart valve prosthesis for replacing a diseased native valve in a patient is provided. The heart valve prosthesis includes a compressible and expandable frame structure and an anchor connected to an outer periphery of the frame structure. The anchor comprises a helical wire having a free end. The valve may further include a valve segment within the frame structure. The valve segment may include a biocompatible one-way valve.
In a second aspect, a heart valve prosthesis for replacing a diseased native valve in a heart of a patient is provided. The valve prosthesis comprises a compressible and expandable frame structure, a valve segment disposed within the frame structure, the valve segment comprising a biocompatible one-way valve, and an anchor connected to an outer periphery of the frame structure, wherein the anchor comprises a helical wire having a free end.
In some embodiments, the free end of the helical wire may be configured to guide the helical wire through a commissure of a native valve of a patient.
In some embodiments, the free end may comprise an atraumatic tip. For example, the free end may comprise a ball tip.
In some embodiments, the free end may be configured for piercing tissue.
In some embodiments, the anchor may comprise a first portion comprising the helical wire and another portion.
In some embodiments, the anchor may comprise a plurality of anchors. The plurality of anchors may comprise at least two helical wires having different diameters. Alternatively, or in combination, the plurality of anchors may comprise at least two helical wires having different winding pitches.
In some embodiments, the helical wire may have a generally tubular shape. The free end of the helical wire may extend radially outward from the tubular shape.
In some embodiments, the helical wire may have a generally frustoconical shape. The free end of the helical wire may extend radially outward from the frustoconical shape.
In some embodiments, the frame structure may be configured for expanding within a native valve of a patient.
In some embodiments, the frame structure may have a compressed state sized and dimensioned for percutaneous insertion and an expanded state sized and dimensioned for implantation in a native valve of a patient.
In some embodiments, the frame structure may comprise first and second opposite ends, the first end extending above a native valve and the second end extending below the native valve when the valve prosthesis is positioned across the native valve.
In some embodiments, the frame structure may comprise an expandable stent.
In some embodiments, the frame structure may comprise a generally tubular expanded shape.
In some embodiments, the frame structure may comprise an expanded outer periphery and a compressed outer periphery when subject to an external radial force. The compressed outer periphery may be slightly smaller in diameter than the expanded outer periphery.
In some embodiments, the frame structure may be balloon-expandable.
In some embodiments, the frame structure may be self-expanding.
In some embodiments, at least a portion of the valve segment may be positioned within at least a portion of the frame structure.
In some embodiments, the valve segment may comprise at least one leaflet having an inner layer and an outer layer. The frame structure may be attached to the outer layer at one or more ends of the frame structure.
In some embodiments, the valve segment may comprise a plurality of leaflets. For example, the valve segment may comprise two leaflets.
In some embodiments, the helical wire may comprise a second end, and wherein the second end is attached to the frame structure. The helical wire may be attached to the frame structure only at the location of the second end.
In some embodiments, the anchor and the frame structure may be adapted to be independently and separately expanded.
In another aspect, a method of replacing a diseased native valve of a patient is provided. The method comprises loading a valve prosthesis into a delivery catheter, the valve prosthesis comprising an expandable frame structure carrying a biocompatible valve segment and an anchor attached to an outer periphery of the frame structure, the anchor comprising a wire having a free end; delivering the valve prosthesis to a target location above a native valve; inserting the valve prosthesis through the native valve to a position posterior the native valve; rotating the wire such that the free end wraps around at least a portion of chordae tendineae below the valve; and expanding the frame structure including the valve segment within the native valve.
In some embodiments, the method may further comprise anchoring the valve prosthesis by rotating the wire until the frame structure is positioned within leaflets of the native valve.
In some embodiments, the method may further comprise anchoring the valve prosthesis by rotating the wire until the wire tightens around the chordae tendineae.
In some embodiments, the frame structure may be balloon-expandable. Expanding the frame structure may comprise expanding a balloon within the frame structure.
In some embodiments, the frame structure may be self-expanding. Expanding the frame structure may comprise removing a sheath of the delivery device from the frame structure.
In some embodiments, the wire may be a helical wire.
In some embodiments, inserting the valve prosthesis may comprise guiding the free end of the wire through a commissure of the native valve. In some embodiments, rotating the wire may comprise rotating the wire through the commissure.
In another aspect, a heart valve prosthesis for replacing a diseased native valve in a patient is provided. The valve prosthesis comprises a compressible and expandable frame structure, a valve segment disposed within the frame structure comprising a biocompatible one-way valve, and an anchor connected to the frame structure and disposed radially outward from the frame structure, wherein the anchor comprises a helical member having a free end.
In some embodiments, the second end of the anchor may be connected to the frame structure.
In some embodiments, the helical member may comprise a wire or a flat ribbon.
These and other embodiments are described in further detail in the following description related to the appended drawing figures.
The novel features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the present disclosure are utilized, and the accompanying drawings of which:
The devices and methods of the present disclosure have other features and advantages which will be apparent from or are set forth in more detail in the accompanying drawings, which are incorporated in and form a part of this specification, and the following Detailed Description, which together serve to explain the principles of the present invention.
In the following detailed description, reference is made to the accompanying figures, which form a part hereof. In the figures, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, figures, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the figures, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are explicitly contemplated herein.
Although certain embodiments and examples are disclosed below, inventive subject matter extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses, and to modifications and equivalents thereof. Thus, the scope of the claims appended hereto is not limited by any of the particular embodiments described below. For example, in any method or process disclosed herein, the acts or operations of the method or process may be performed in any suitable sequence and are not necessarily limited to any particular disclosed sequence. Various operations may be described as multiple discrete operations in turn, in a manner that may be helpful in understanding certain embodiments, however, the order of description should not be construed to imply that these operations are order dependent. Additionally, the structures, systems, and/or devices described herein may be embodied as integrated components or as separate components.
For purposes of comparing various embodiments, certain aspects and advantages of these embodiments are described. Not necessarily all such aspects or advantages are achieved by any particular embodiment. Thus, for example, various embodiments may be carried out in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other aspects or advantages as may also be taught or suggested herein.
The present disclosure is described in relation to deployment of systems, devices, or methods for treatment of a diseased native valve of the heart, for example a mitral valve. However, one of skill in the art will appreciate that this is not intended to be limiting and the devices and methods disclosed herein may be used in other anatomical areas and in other surgical procedures.
For convenience in explanation and accurate definition in the appended claims, the terms “up” or “upper”, “down” or “lower”, “inside” and “outside” are used to describe features of the embodiments with reference to the positions of such features as displayed in the figures.
In many respects the modifications of the various figures resemble those of preceding modifications and the same reference numerals followed by subscripts “a”, “b”, “c”, and “d” designate corresponding parts.
Turning now to the drawings, wherein like components are designated by like reference numerals throughout the various figures, attention is directed to
The exemplary valve prosthesis 10 will now be described with reference to
Exemplary frame structure 12 is configured like a stent. The frame has an expanded state and a collapsed or compressed state. The compressed state is sized and dimensioned for percutaneous insertion and the expanded state sized and dimensioned for implantation in a native valve of a patient. In various embodiments, the frame structure 12 comprises an expanded outer periphery and a compressed outer periphery when subject to an external radial force, the compressed outer periphery being slightly smaller in diameter than the expanded outer periphery. The frame structure 12 is shown in the expanded, deployed state in
The exemplary frame structure 12 is a scaffold in a diamond pattern formed from a shape memory material (e.g. NiTi). One of ordinary skill in the art will appreciate from the description herein that many other structures, materials, and configurations may be employed for the frame structure 12. For example, the frame structure 12 may be formed of a polymer of sufficient elasticity. The frame structure 12 may be formed of a combination of a metal and polymer, such as a metal (e.g. shape memory material) covered in polymer. The frame structure 12 may include a variety of patterns besides diamond shapes.
Valve prosthesis 10 includes a valve segment 14 within the frame structure 12. The exemplary valve segment 14 is expandable and collapsible. In the illustrated embodiment, the valve segment 14 is affixed within the frame structure 12 and expands and collapses with the frame structure 12. Valve segment is used somewhat interchangeably with prosthetic valve leaflet and generally refers to the prosthetic leaflets and frame. As used herein, “prosthetic valve” may refer to all manner of prosthetic and artificial replacement valves including tissue (biological) valves, tissue-engineered valves, polymer valves (e.g. biodegradable polymer valves), and even certain mechanical valves.
In the illustrated embodiment, frame structure 12 is a closed frame such that blood flow is forced through valve segment 14 therein. One or more skirts and/or seals may help force blood through valve segment 14.
Valve segment 14 can be configured as would be understood by one of skill from the description herein. The valve segment 14 can be similar to existing transcatheter valves. The valve segment 14 can be similar to existing surgical tissue valves, and mechanical valves. In various embodiments, the valve segment 14 includes leaflets 16 formed of multi-layered materials for preferential function. At least one leaflet 16 may have an inner layer and an outer layer. In various embodiments, the leaflet 16 is connected to a valve structure which in turn is connected to the frame structure 12. The valve structure may be connected to the frame structure 12 before or after the frame structure 12 has been deployed adjacent a native valve. In various embodiments, the leaflet 16 is attached to the frame structure 12 directly. The leaflet 16 may have an inner layer and an outer layer, with the outer layer attached to the frame structure 12. The leaflet 16 may be attached to an end of the frame structure 12. Alternatively, or in combination, the leaflet 16 may be attached to an intermediate portion of the frame structure 12. In various embodiments, the valve segment 14 includes a plurality of leaflets 16, such as two, three, or more leaflets. In the illustrated embodiment, the valve segment 14 includes three leaflets 16 which are attached to frame structure 12. An exemplary leaflet 16 is shown in
Turning back to
Although referred to as an anchor, one will appreciate that anchor 15 does not require performing an anchor function in the traditional sense. As will be described in more detail below, the anchor guides valve prosthesis 10 into a desired position within a native valve. The anchor 15 may also mitigate against undesired entanglement and disturbances to the chordae tendineae and valve leaflets of the mitral valve.
Wire 20 is formed of a material having sufficient rigidity to hold a predetermined shape. In the exemplary embodiment, the wire 20 is formed of a shape memory material (e.g. NiTi). It may be desirable for at least an end portion to be relatively rigid such that it can exert a force to move chordae tendineae, while still retaining flexibility to be collapsed within a catheter. In various embodiments, the end portion (including free end 22) only needs sufficient rigidity to hold its shape and will deform under a load. For example, the end portion may be configured with similar rigidity to a guidewire, or slightly stiffer.
In various embodiments, the anchor 15 comprises a helical member. The helical member may comprise a helical wire or flat ribbon. The helical member may comprise a three-dimensional surface as described herein.
In various embodiments, the anchor 15 may comprise a first portion comprising the helical wire 20 and another portion. Alternatively or in combination, the anchor 15 may comprise a plurality of helical wires 20. For example, the anchor 15 may comprise at least two helical wires 20 having the same or different diameters. Alternatively or in combination, the anchor 15 may comprise at least two helical wires 20 having the same or different winding pitches.
In various embodiments, the anchor 15 may comprise a plurality of anchors, for example a plurality of helical wires 20 as described herein.
In the illustrated embodiment, valve prosthesis 10 is configured for replacing a mitral valve and free end 22 is configured for insertion through a commissure.
With continued reference to
In various embodiments, wire 20 has varying stiffness along its length. The wire 20 may have two or more segments of differing stiffness and/or the stiffness may transition over its length. In various embodiments, wire 20 is attached to frame 12 at multiple points such that free end 22 is relatively flexible and the wire 20 is more rigid along portions where it is attached to the frame structure 12.
In various embodiments, free end 22 extends radially outward from frame structure 12, and in particular the remainder of wire 20. As will be described below, the free end 22 is configured to encircle a larger radius than the main coils of the wire 20. For example, when the main coils of wire 20 have a generally tubular shape, the free end 22 may extend radially outward from the tubular shape. When the main coils of wire 20 have a generally helical shape, the free end 22 may extend radially outward from the helical shape. When the main coils of wire 20 have a generally frustoconical shape, the free end 22 may extend radially outward from the frustoconical shape. The larger diameter facilitates capturing of the valve leaflets and/or chordae tendineae within the sweep of the free end 22 during rotation as will be described in more detail below.
The method of implanting valve prosthesis 10 in accordance with the present disclosure will now be described with reference to
Prior to implantation, valve prosthesis 10 is collapsed and loaded into a delivery device 30, for example, a delivery catheter. The valve system is optionally primed before or after loading into the delivery catheter 30.
Next, the delivery catheter 30 is inserted through an introducer into a vessel. The delivery catheter 30 can be guided over a guidewire to a target location using the Seldinger technique. In the illustrated embodiment, the delivery catheter 30 is guided to the left atrium 25 through a transseptal puncture 27 in conventional fashion as shown in
Turning to
Turning to
If the clinician desires to remove or reposition the valve, the helical wire 20 can be counter-rotated to back out the device 10 from the native valve 4. The implant rotation procedure can then be repeated.
Frame structure 12 is expanded once valve 10 is in the desired location as shown in
Once the frame structure 12 is expanded the entire valve assembly 10 is released from the delivery catheter 30 and the delivery catheter 30 is removed as shown in
In the illustrated embodiment, the valve structure 14 and frame structure 12 are deployed together. One of ordinary skill in the art will appreciate, however, that the frame structure 12 can be deployed first and then receive the prosthetic valve segment 14.
In various embodiments, valve prosthesis 10 does not include a valve segment 14. Instead, the frame structure 12 and anchor 15 are positioned within the native valve 4. The frame structure 12 is configured to receive a valve segment 14 delivered separately. In certain embodiments, the frame structure 12 can be configured to receive one of several valve sizes and types. In this manner, a clinician can choose the proper valve for the individual patient.
In the illustrated embodiment, the helical wire 20 of anchor 15 guides the valve system 10 along a desired axis into position adjacent the native valve 4. The wire 20 also provides an initial anchoring. The valve prosthesis 10 is finally anchored when the frame structure 12 is expanded within the native valve 4. The frame structure 12 dilates the valve leaflets 14 and the compressive force fixes the valve prosthesis 10 into position. Thereafter tissue ingrowth ensures the valve prosthesis 10 remains seated and does not migrate.
The valve device in accordance with the present disclosure provides several advantages over conventional valve systems. Embodiments described herein provide an easy-to-use, repositionable device. Unlike conventional valve systems, the valve prosthesis described herein reduces the risk of injuring or tearing chordae. Typical mitral valve replacement systems involve implanting a prosthetic annulus or ring around the valve. The ring increases the circumference of the valve and risks occluding the entry to the aortic valve. The valve device described herein overcomes these and other problems.
When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.
Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.
When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.
Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.
As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “X” is disclosed the “less than or equal to X” as well as “greater than or equal to X” (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
The foregoing descriptions of specific embodiments of the present invention have been presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed, and obviously many modifications, changes, substitutions, alternatives, and variations are possible in light of the above teaching. The embodiments were chosen and described to best explain the principles of the invention and its practical application, to thereby enable others skilled in the art to best utilize the invention and various embodiments with various modifications as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the Claims appended hereto and their equivalents.
This application claims the benefit of U.S. Provisional Patent Application No. 62/720,853, filed on Aug. 21, 2018, entitled Prosthetic Cardiac Valve Devices, Systems, and Methods; which is incorporated herein for all purposes in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4725274 | Lane et al. | Feb 1988 | A |
5002563 | Pyka et al. | Mar 1991 | A |
5327905 | Avitall | Jul 1994 | A |
5356424 | Buzerak et al. | Oct 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5582616 | Bolduc et al. | Dec 1996 | A |
5716397 | Myers | Feb 1998 | A |
5755601 | Jones | May 1998 | A |
5779669 | Haissaguerre et al. | Jul 1998 | A |
5873835 | Hastings et al. | Feb 1999 | A |
5944690 | Falwell et al. | Aug 1999 | A |
5997526 | Giba et al. | Dec 1999 | A |
6048339 | Zirps et al. | Apr 2000 | A |
6053873 | Govari et al. | Apr 2000 | A |
6254550 | McNamara et al. | Jul 2001 | B1 |
6419695 | Gabbay | Jul 2002 | B1 |
6419696 | Ortiz et al. | Jul 2002 | B1 |
6530952 | Vesely | Mar 2003 | B2 |
6533783 | Töllner | Mar 2003 | B1 |
6641553 | Chee et al. | Nov 2003 | B1 |
6752813 | Goldfarb et al. | Jun 2004 | B2 |
6869444 | Gabbay | Mar 2005 | B2 |
6908478 | Alferness et al. | Jun 2005 | B2 |
6964684 | Ortiz et al. | Nov 2005 | B2 |
6974476 | McGuckin, Jr. et al. | Dec 2005 | B2 |
7077861 | Spence | Jul 2006 | B2 |
7101395 | Tremulis et al. | Sep 2006 | B2 |
7125421 | Tremulis et al. | Oct 2006 | B2 |
7160322 | Gabbay | Jan 2007 | B2 |
7175656 | Khairkhahan | Feb 2007 | B2 |
7201771 | Lane | Apr 2007 | B2 |
7226467 | Lucatero et al. | Jun 2007 | B2 |
7381219 | Salahieh et al. | Jan 2008 | B2 |
7329279 | Haug et al. | Feb 2008 | B2 |
7445631 | Salahieh et al. | Nov 2008 | B2 |
7470285 | Nugent et al. | Dec 2008 | B2 |
7527647 | Spence | May 2009 | B2 |
7534261 | Friedman | May 2009 | B2 |
7563267 | Goldfarb et al. | Jul 2009 | B2 |
7594903 | Webler et al. | Sep 2009 | B2 |
7604646 | Goldfarb et al. | Oct 2009 | B2 |
7608091 | Goldfarb et al. | Oct 2009 | B2 |
7618449 | Tremulis et al. | Nov 2009 | B2 |
7621948 | Herrmann et al. | Nov 2009 | B2 |
7666204 | Thornton et al. | Feb 2010 | B2 |
7704269 | St. Goar et al. | Apr 2010 | B2 |
7731705 | Wardle | Jun 2010 | B2 |
7748389 | Salahieh et al. | Jul 2010 | B2 |
7749266 | Forster et al. | Jul 2010 | B2 |
7780725 | Haug et al. | Aug 2010 | B2 |
7799069 | Bailey et al. | Sep 2010 | B2 |
7811296 | Goldfarb et al. | Oct 2010 | B2 |
7824442 | Salahieh et al. | Nov 2010 | B2 |
7824443 | Salahieh et al. | Nov 2010 | B2 |
7846203 | Cribier | Dec 2010 | B2 |
7942927 | Kaye et al. | May 2011 | B2 |
7947075 | Goetz et al. | May 2011 | B2 |
7951195 | Antonsson et al. | May 2011 | B2 |
7959666 | Salahieh et al. | Jun 2011 | B2 |
7988724 | Salahieh et al. | Aug 2011 | B2 |
8021421 | Fogarty et al. | Sep 2011 | B2 |
8052749 | Salahieh et al. | Nov 2011 | B2 |
8052750 | Tuval et al. | Nov 2011 | B2 |
8062355 | Figulla et al. | Nov 2011 | B2 |
8070800 | Lock et al. | Dec 2011 | B2 |
8075615 | Eberhardt et al. | Dec 2011 | B2 |
8096985 | Legaspi et al. | Jan 2012 | B2 |
8147541 | Forster et al. | Apr 2012 | B2 |
8147542 | Maisano et al. | Apr 2012 | B2 |
8182528 | Salahieh et al. | May 2012 | B2 |
8216256 | Raschdorf et al. | Jul 2012 | B2 |
8236049 | Rowe et al. | Aug 2012 | B2 |
8241351 | Cabiri | Aug 2012 | B2 |
8251977 | Partlett | Aug 2012 | B2 |
8252050 | Maisano et al. | Aug 2012 | B2 |
8287584 | Salahieh et al. | Oct 2012 | B2 |
8313526 | Hoffman et al. | Nov 2012 | B2 |
8323241 | Salahieh et al. | Dec 2012 | B2 |
8323336 | Hill et al. | Dec 2012 | B2 |
8328868 | Paul et al. | Dec 2012 | B2 |
8343213 | Salahieh et al. | Jan 2013 | B2 |
8348995 | Tuval et al. | Jan 2013 | B2 |
8348996 | Tuval et al. | Jan 2013 | B2 |
8366767 | Zhang | Feb 2013 | B2 |
8403981 | Forster et al. | Mar 2013 | B2 |
8403983 | Quadri et al. | Mar 2013 | B2 |
8414643 | Tuval et al. | Apr 2013 | B2 |
8414644 | Quadri et al. | Apr 2013 | B2 |
8414645 | Dwork et al. | Apr 2013 | B2 |
8425593 | Braido et al. | Apr 2013 | B2 |
8449599 | Chau et al. | May 2013 | B2 |
8454686 | Alkhatib | Jun 2013 | B2 |
8465541 | Dwork | Jun 2013 | B2 |
8500800 | Maisano et al. | Aug 2013 | B2 |
8512401 | Murray et al. | Aug 2013 | B2 |
8523881 | Cabiri et al. | Sep 2013 | B2 |
8545553 | Zipory et al. | Oct 2013 | B2 |
8556963 | Tremulis et al. | Oct 2013 | B2 |
8562645 | Stone et al. | Oct 2013 | B2 |
8562673 | Yeung et al. | Oct 2013 | B2 |
8579962 | Salahieh et al. | Nov 2013 | B2 |
8603157 | Seguin et al. | Dec 2013 | B2 |
8603160 | Salahieh et al. | Dec 2013 | B2 |
8623075 | Murray et al. | Jan 2014 | B2 |
8628570 | Seguin | Jan 2014 | B2 |
8641727 | Starksen et al. | Feb 2014 | B2 |
8652202 | Alon et al. | Feb 2014 | B2 |
8652203 | Quadri et al. | Feb 2014 | B2 |
8657872 | Seguin | Feb 2014 | B2 |
8685086 | Navia | Apr 2014 | B2 |
8696693 | Najafi et al. | Apr 2014 | B2 |
8715300 | Najafi et al. | May 2014 | B2 |
8715342 | Zipory et al. | May 2014 | B2 |
8740976 | Tran et al. | Jun 2014 | B2 |
8784479 | Antonsson et al. | Jul 2014 | B2 |
8790367 | Nguyen et al. | Jul 2014 | B2 |
8808368 | Maisano et al. | Aug 2014 | B2 |
8828078 | Salahieh et al. | Sep 2014 | B2 |
8834564 | Tuval et al. | Sep 2014 | B2 |
8840663 | Salahieh et al. | Sep 2014 | B2 |
8840664 | Karapetian et al. | Sep 2014 | B2 |
8845588 | Bruszewski | Sep 2014 | B2 |
8852271 | Murray et al. | Oct 2014 | B2 |
8876893 | Dwork et al. | Nov 2014 | B2 |
8876894 | Tuval et al. | Nov 2014 | B2 |
8876895 | Tuval et al. | Nov 2014 | B2 |
8900294 | Paniagua et al. | Dec 2014 | B2 |
8911494 | Hammer et al. | Dec 2014 | B2 |
8920369 | Salahieh et al. | Dec 2014 | B2 |
8926690 | Kowalsky | Jan 2015 | B2 |
8926696 | Cabiri et al. | Jan 2015 | B2 |
8926697 | Gross et al. | Jan 2015 | B2 |
8940002 | Goertzen | Jan 2015 | B2 |
8940044 | Hammer et al. | Jan 2015 | B2 |
8951299 | Paul et al. | Feb 2015 | B2 |
8986371 | Quill et al. | Mar 2015 | B2 |
8998980 | Shipley et al. | Apr 2015 | B2 |
9005273 | Salahieh et al. | Apr 2015 | B2 |
9011515 | Schweich et al. | Apr 2015 | B2 |
9011523 | Seguin | Apr 2015 | B2 |
9011530 | Reich et al. | Apr 2015 | B2 |
9017408 | Siegal et al. | Apr 2015 | B2 |
9023100 | Quadri et al. | May 2015 | B2 |
9034032 | McLean et al. | May 2015 | B2 |
9039757 | McLean et al. | May 2015 | B2 |
9056009 | Keränen | Jun 2015 | B2 |
9061120 | Osypka et al. | Jun 2015 | B2 |
9078747 | Conklin | Jul 2015 | B2 |
9095431 | Yu et al. | Aug 2015 | B2 |
9119719 | Zipory et al. | Sep 2015 | B2 |
9125739 | Paniagua et al. | Sep 2015 | B2 |
9125740 | Morriss et al. | Sep 2015 | B2 |
9155619 | Líu et al. | Oct 2015 | B2 |
9168129 | Valdez et al. | Oct 2015 | B2 |
9168131 | Yohanan et al. | Oct 2015 | B2 |
9173713 | Hart et al. | Nov 2015 | B2 |
9173737 | Hill et al. | Nov 2015 | B2 |
9180006 | Keränen | Nov 2015 | B2 |
9226823 | Dwork | Jan 2016 | B2 |
9232995 | Kovalsky et al. | Jan 2016 | B2 |
9277994 | Miller et al. | Mar 2016 | B2 |
9289297 | Wilson et al. | Mar 2016 | B2 |
9295547 | Costello et al. | Mar 2016 | B2 |
9301756 | Wardle | Apr 2016 | B2 |
9301836 | Buchbinder et al. | Apr 2016 | B2 |
9320597 | Savage et al. | Apr 2016 | B2 |
9343224 | Zilbershlag | May 2016 | B2 |
9358110 | Paul et al. | Jun 2016 | B2 |
9414915 | Lombardi et al. | Aug 2016 | B2 |
9427315 | Schweich et al. | Aug 2016 | B2 |
9439757 | Wallace et al. | Sep 2016 | B2 |
9468525 | Kovalsky | Oct 2016 | B2 |
9474606 | Zipory et al. | Oct 2016 | B2 |
9474840 | Siess | Oct 2016 | B2 |
9480559 | Vidlund et al. | Nov 2016 | B2 |
9492273 | Wallace et al. | Nov 2016 | B2 |
9526487 | Rahmani | Dec 2016 | B2 |
9526609 | Salahieh et al. | Dec 2016 | B2 |
9532868 | Braido | Jan 2017 | B2 |
9532870 | Cooper et al. | Jan 2017 | B2 |
9561102 | Rust et al. | Feb 2017 | B2 |
9572662 | Morriss et al. | Feb 2017 | B2 |
9579196 | Morriss et al. | Feb 2017 | B2 |
9579198 | Deem et al. | Feb 2017 | B2 |
9585751 | Morriss et al. | Mar 2017 | B2 |
9636224 | Zipory et al. | May 2017 | B2 |
9636481 | Campbell et al. | May 2017 | B2 |
9662202 | Quill et al. | May 2017 | B2 |
9662206 | Börtlein et al. | May 2017 | B2 |
9662209 | Gross et al. | May 2017 | B2 |
9675454 | Vidlund et al. | Jun 2017 | B2 |
9681952 | Hacohen et al. | Jun 2017 | B2 |
9687343 | Börtlein et al. | Jun 2017 | B2 |
9724192 | Sheps et al. | Aug 2017 | B2 |
9730790 | Quadri et al. | Aug 2017 | B2 |
9730793 | Reich et al. | Aug 2017 | B2 |
9744031 | Girard et al. | Aug 2017 | B2 |
9744038 | Dahlgren et al. | Aug 2017 | B2 |
9750605 | Ganesan et al. | Sep 2017 | B2 |
9763779 | Börtlein et al. | Sep 2017 | B2 |
9763780 | Morriss et al. | Sep 2017 | B2 |
9814611 | Cartledge et al. | Nov 2017 | B2 |
9827090 | Hill et al. | Nov 2017 | B2 |
9861480 | Zakai et al. | Jan 2018 | B2 |
9867700 | Bakis et al. | Jan 2018 | B2 |
9867702 | Keränen et al. | Jan 2018 | B2 |
9877833 | Bishop et al. | Jan 2018 | B1 |
9883941 | Hastings et al. | Feb 2018 | B2 |
9889003 | Börtlein et al. | Feb 2018 | B2 |
9895221 | Vidlund | Feb 2018 | B2 |
9895222 | Zeng et al. | Feb 2018 | B2 |
9901444 | Valdez et al. | Feb 2018 | B2 |
9918840 | Reich et al. | Mar 2018 | B2 |
D815744 | Ratz et al. | Apr 2018 | S |
9949825 | Braido et al. | Apr 2018 | B2 |
9949828 | Sheps et al. | Apr 2018 | B2 |
9950142 | Eversull et al. | Apr 2018 | B2 |
9968452 | Sheps et al. | May 2018 | B2 |
9974647 | Ganesan et al. | May 2018 | B2 |
9974650 | Nguyen-Thien-Nhon et al. | May 2018 | B2 |
9999502 | Nasr et al. | Jun 2018 | B2 |
9999504 | Czyscon et al. | Jun 2018 | B2 |
10004599 | Rabito et al. | Jun 2018 | B2 |
10016271 | Morriss et al. | Jul 2018 | B2 |
10016272 | Spence et al. | Jul 2018 | B2 |
10028827 | Morriss et al. | Jul 2018 | B2 |
10028832 | Quill et al. | Jul 2018 | B2 |
10029037 | Muller et al. | Jul 2018 | B2 |
10034747 | Harewood | Jul 2018 | B2 |
10034749 | Spence | Jul 2018 | B2 |
10034750 | Morriss et al. | Jul 2018 | B2 |
10039637 | Maimon et al. | Aug 2018 | B2 |
10045846 | Bonyuet et al. | Aug 2018 | B2 |
10052198 | Chau | Aug 2018 | B2 |
10052199 | Spence et al. | Aug 2018 | B2 |
10058318 | Tegzes | Aug 2018 | B2 |
10058321 | Sampson et al. | Aug 2018 | B2 |
10064719 | Börtlein et al. | Sep 2018 | B2 |
10070954 | Braido et al. | Sep 2018 | B2 |
10092400 | Jimenez et al. | Oct 2018 | B2 |
10098734 | Hoang | Oct 2018 | B2 |
10105217 | Keränen | Oct 2018 | B2 |
10105224 | Buchbinder et al. | Oct 2018 | B2 |
10130464 | Meiri et al. | Nov 2018 | B2 |
10130471 | Keränen et al. | Nov 2018 | B2 |
10143552 | Wallace et al. | Dec 2018 | B2 |
10149759 | Naor | Dec 2018 | B2 |
10172708 | Anderson | Jan 2019 | B2 |
10172711 | Keränen | Jan 2019 | B2 |
10179042 | Braido et al. | Jan 2019 | B2 |
10195021 | Keränen et al. | Feb 2019 | B2 |
10195025 | Levi et al. | Feb 2019 | B2 |
10195027 | Nasr | Feb 2019 | B2 |
10195028 | Hosmer et al. | Feb 2019 | B2 |
10195029 | Keränen | Feb 2019 | B2 |
10201418 | Biadillah et al. | Feb 2019 | B2 |
10206775 | Kovalsky et al. | Feb 2019 | B2 |
10213307 | Dwork et al. | Feb 2019 | B2 |
10226330 | Spence et al. | Mar 2019 | B2 |
10226334 | Rowe et al. | Mar 2019 | B2 |
10226339 | Spence | Mar 2019 | B2 |
10238489 | Conklin | Mar 2019 | B2 |
10251749 | Zerkowski et al. | Apr 2019 | B2 |
10258464 | Delaloye et al. | Apr 2019 | B2 |
10258468 | Deem et al. | Apr 2019 | B2 |
10265169 | Desrosiers et al. | Apr 2019 | B2 |
10271950 | Neustadter | Apr 2019 | B2 |
10299917 | Morriss et al. | May 2019 | B2 |
10299921 | Dale et al. | May 2019 | B2 |
10321988 | Gorman et al. | Jun 2019 | B2 |
10321989 | Keränen | Jun 2019 | B2 |
10327743 | St. Goar et al. | Jun 2019 | B2 |
10327766 | Zerkowski et al. | Jun 2019 | B2 |
10335277 | Crisostomo et al. | Jul 2019 | B2 |
10338724 | Zhao | Jul 2019 | B2 |
10350066 | Cooper et al. | Jul 2019 | B2 |
10357351 | Cooper et al. | Jul 2019 | B2 |
10357634 | Simmons et al. | Jul 2019 | B2 |
10363130 | Armer et al. | Jul 2019 | B2 |
10363131 | Eidenschink et al. | Jul 2019 | B2 |
10368986 | Gosal et al. | Aug 2019 | B2 |
10368990 | Noe et al. | Aug 2019 | B2 |
10376266 | Herman et al. | Aug 2019 | B2 |
10376360 | Bruchman et al. | Aug 2019 | B2 |
10376363 | Quadri et al. | Aug 2019 | B2 |
10398547 | Li et al. | Sep 2019 | B2 |
10426608 | Salahieh et al. | Oct 2019 | B2 |
10433961 | McLean | Oct 2019 | B2 |
10463479 | Manash | Nov 2019 | B2 |
10470881 | Noe et al. | Nov 2019 | B2 |
10478291 | Nguyen et al. | Nov 2019 | B2 |
10500048 | Khairkhahan et al. | Dec 2019 | B2 |
10507104 | Zhang et al. | Dec 2019 | B2 |
10512541 | Zerkowski et al. | Dec 2019 | B2 |
10524901 | Quadri et al. | Jan 2020 | B2 |
10548729 | Zipory et al. | Feb 2020 | B2 |
10568737 | Noe et al. | Feb 2020 | B2 |
10575951 | Johnson et al. | Mar 2020 | B2 |
10603165 | Maimon et al. | Mar 2020 | B2 |
10639154 | Seguin | May 2020 | B2 |
10653524 | Khairkhahan et al. | May 2020 | B2 |
10660753 | Pham et al. | May 2020 | B2 |
10687938 | Patel et al. | Jun 2020 | B2 |
10695160 | Lashinski et al. | Jun 2020 | B2 |
10702386 | Khairkhahan et al. | Jul 2020 | B2 |
10709552 | Backus et al. | Jul 2020 | B2 |
10716662 | Delaloye et al. | Jul 2020 | B2 |
10722351 | Griffin | Jul 2020 | B2 |
10722352 | Spence | Jul 2020 | B2 |
10722353 | Levi | Jul 2020 | B2 |
10729542 | Howard et al. | Aug 2020 | B2 |
10743991 | Brown | Aug 2020 | B2 |
10751180 | Schewel | Aug 2020 | B2 |
10751184 | Reich et al. | Aug 2020 | B2 |
10765514 | Iflah et al. | Sep 2020 | B2 |
10813749 | Nguyen et al. | Oct 2020 | B2 |
10828153 | Noe et al. | Nov 2020 | B2 |
10856970 | Tuval et al. | Dec 2020 | B2 |
10869755 | Granada et al. | Dec 2020 | B2 |
10888420 | Bateman et al. | Jan 2021 | B2 |
10912644 | Argento | Feb 2021 | B2 |
10973629 | Levi et al. | Apr 2021 | B2 |
10973630 | Tonianni et al. | Apr 2021 | B2 |
11007057 | Pham et al. | May 2021 | B2 |
11020221 | Arcaro et al. | Jun 2021 | B2 |
11039922 | Konno | Jun 2021 | B2 |
11103345 | Levi et al. | Aug 2021 | B2 |
11147670 | Hayoz et al. | Oct 2021 | B2 |
11234818 | Zerkowski et al. | Feb 2022 | B2 |
11547563 | Keränen et al. | Jan 2023 | B2 |
11672657 | Argento | Jun 2023 | B2 |
11833034 | Argento | Dec 2023 | B2 |
11986389 | Argento | May 2024 | B2 |
12053371 | Adamek-Bowers | Aug 2024 | B2 |
20020173841 | Ortiz et al. | Nov 2002 | A1 |
20030114913 | Spenser et al. | Jun 2003 | A1 |
20030233142 | Morales et al. | Dec 2003 | A1 |
20040039442 | St. Goar et al. | Feb 2004 | A1 |
20040044350 | Martin et al. | Mar 2004 | A1 |
20050137686 | Salahieh et al. | Jun 2005 | A1 |
20050137687 | Salahieh et al. | Jun 2005 | A1 |
20050137691 | Salahieh et al. | Jun 2005 | A1 |
20050137694 | Haug et al. | Jun 2005 | A1 |
20050137696 | Salahieh et al. | Jun 2005 | A1 |
20050165344 | Dobak, III | Jul 2005 | A1 |
20050240202 | Shennib et al. | Oct 2005 | A1 |
20050277839 | Alderman et al. | Dec 2005 | A1 |
20060009841 | McGuckin, Jr. et al. | Jan 2006 | A1 |
20060052821 | Abbot et al. | Mar 2006 | A1 |
20060074484 | Huber | Apr 2006 | A1 |
20060178700 | Quinn | Aug 2006 | A1 |
20060195134 | Crittenden | Aug 2006 | A1 |
20060217762 | Maahs et al. | Sep 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20060293698 | Douk | Dec 2006 | A1 |
20070027533 | Douk | Feb 2007 | A1 |
20070038292 | Danielpour | Feb 2007 | A1 |
20070051377 | Douk et al. | Mar 2007 | A1 |
20070055206 | To et al. | Mar 2007 | A1 |
20070118151 | Davidson | May 2007 | A1 |
20070142907 | Moaddeb et al. | Jun 2007 | A1 |
20070185572 | Solem et al. | Aug 2007 | A1 |
20070255396 | Douk et al. | Nov 2007 | A1 |
20070293724 | Saadat et al. | Dec 2007 | A1 |
20070293943 | Quinn | Dec 2007 | A1 |
20080004696 | Vesely | Jan 2008 | A1 |
20080004697 | Lichtenstein et al. | Jan 2008 | A1 |
20080200980 | Robin et al. | Aug 2008 | A1 |
20080208327 | Rowe | Aug 2008 | A1 |
20080275503 | Spence et al. | Nov 2008 | A1 |
20080275540 | Wen | Nov 2008 | A1 |
20090030504 | Weber | Jan 2009 | A1 |
20090088836 | Bishop et al. | Apr 2009 | A1 |
20090093826 | Warder-Gabaldon | Apr 2009 | A1 |
20090138079 | Tuval et al. | May 2009 | A1 |
20090157174 | Yoganathan et al. | Jun 2009 | A1 |
20090192601 | Raffee et al. | Jul 2009 | A1 |
20090209950 | Starksen | Aug 2009 | A1 |
20090222026 | Rothstein et al. | Sep 2009 | A1 |
20090276040 | Rowe et al. | Nov 2009 | A1 |
20090299471 | Keranen | Dec 2009 | A1 |
20100010520 | Takahashi et al. | Jan 2010 | A1 |
20100049239 | McGuckin, Jr. et al. | Feb 2010 | A1 |
20100076497 | Zwirkoski | Mar 2010 | A1 |
20100076549 | Keidar | Mar 2010 | A1 |
20100094406 | Leprince et al. | Apr 2010 | A1 |
20100185172 | Fabro | Jul 2010 | A1 |
20100198056 | Fabro et al. | Aug 2010 | A1 |
20100198192 | Serina et al. | Aug 2010 | A1 |
20100198208 | Napp et al. | Aug 2010 | A1 |
20100217385 | Thompson et al. | Aug 2010 | A1 |
20100312333 | Navia et al. | Dec 2010 | A1 |
20110022164 | Quinn et al. | Jan 2011 | A1 |
20110040366 | Goetz | Feb 2011 | A1 |
20110046600 | Crank | Feb 2011 | A1 |
20110224785 | Hacohen | Sep 2011 | A1 |
20110245911 | Quill | Oct 2011 | A1 |
20110288637 | De | Nov 2011 | A1 |
20110313515 | Quadri et al. | Dec 2011 | A1 |
20110319989 | Lane et al. | Dec 2011 | A1 |
20120022633 | Olson | Jan 2012 | A1 |
20120053680 | Bolling et al. | Mar 2012 | A1 |
20120143316 | Seguin et al. | Jun 2012 | A1 |
20120197388 | Khairkhahan et al. | Aug 2012 | A1 |
20120203333 | McGuckin, Jr. et al. | Aug 2012 | A1 |
20120221101 | Moaddeb et al. | Aug 2012 | A1 |
20120277734 | Geotz et al. | Nov 2012 | A1 |
20120277853 | Rothstein | Nov 2012 | A1 |
20130006352 | Yaron | Jan 2013 | A1 |
20130023985 | Khairkhahan et al. | Jan 2013 | A1 |
20130035758 | Seguin et al. | Feb 2013 | A1 |
20130079873 | Migliazza et al. | Mar 2013 | A1 |
20130116779 | Weber | May 2013 | A1 |
20130123912 | Tung et al. | May 2013 | A1 |
20130172992 | Gross | Jul 2013 | A1 |
20130253643 | Rolando et al. | Sep 2013 | A1 |
20130274873 | Delaloye et al. | Oct 2013 | A1 |
20130325110 | Khalil et al. | Dec 2013 | A1 |
20140005768 | Thomas et al. | Jan 2014 | A1 |
20140031928 | Murphy et al. | Jan 2014 | A1 |
20140081154 | Toth | May 2014 | A1 |
20140200649 | Essinger et al. | Jul 2014 | A1 |
20140228943 | Stigall et al. | Aug 2014 | A1 |
20140249621 | Eidenschink | Sep 2014 | A1 |
20140257467 | Lane et al. | Sep 2014 | A1 |
20140277382 | Dolan et al. | Sep 2014 | A1 |
20140277409 | Börtlein et al. | Sep 2014 | A1 |
20140324163 | Keränen et al. | Oct 2014 | A1 |
20140379074 | Spence et al. | Dec 2014 | A1 |
20150005764 | Hanson et al. | Jan 2015 | A1 |
20150018876 | Ewers et al. | Jan 2015 | A1 |
20150039082 | Keranen | Feb 2015 | A1 |
20150051709 | Vasquez et al. | Feb 2015 | A1 |
20150134055 | Spence et al. | May 2015 | A1 |
20150173897 | Raanani et al. | Jun 2015 | A1 |
20150250480 | Featherstone | Sep 2015 | A1 |
20150265403 | Keränen | Sep 2015 | A1 |
20150272737 | Dale et al. | Oct 2015 | A1 |
20150297346 | Duffy et al. | Oct 2015 | A1 |
20150305863 | Gray et al. | Oct 2015 | A1 |
20150327994 | Morriss et al. | Nov 2015 | A1 |
20150328000 | Ratz et al. | Nov 2015 | A1 |
20150335290 | Hunter | Nov 2015 | A1 |
20150335426 | Lim et al. | Nov 2015 | A1 |
20150351735 | Keränen et al. | Dec 2015 | A1 |
20150351908 | Keränen et al. | Dec 2015 | A1 |
20150351911 | Keränen et al. | Dec 2015 | A1 |
20160089126 | Guo | Mar 2016 | A1 |
20160095705 | Keränen et al. | Apr 2016 | A1 |
20160113764 | Sheahan et al. | Apr 2016 | A1 |
20160143689 | Ditter | May 2016 | A1 |
20160143731 | Backus et al. | May 2016 | A1 |
20160166380 | Seguin et al. | Jun 2016 | A1 |
20160199177 | Spence | Jul 2016 | A1 |
20160206853 | Bolduc et al. | Jul 2016 | A1 |
20160228247 | Maimon et al. | Aug 2016 | A1 |
20160235526 | Lashinski et al. | Aug 2016 | A1 |
20160235529 | Ma et al. | Aug 2016 | A1 |
20160242902 | Morriss et al. | Aug 2016 | A1 |
20160242906 | Morriss et al. | Aug 2016 | A1 |
20160324637 | Hlavka et al. | Nov 2016 | A1 |
20160324639 | Nguyen et al. | Nov 2016 | A1 |
20160331523 | Chau et al. | Nov 2016 | A1 |
20160346080 | Righini et al. | Dec 2016 | A1 |
20170056163 | Tayeb et al. | Mar 2017 | A1 |
20170071732 | Conklin et al. | Mar 2017 | A1 |
20170079790 | Vidlund et al. | Mar 2017 | A1 |
20170112624 | Patel | Apr 2017 | A1 |
20170119524 | Salahieh et al. | May 2017 | A1 |
20170128203 | Zhang et al. | May 2017 | A1 |
20170128204 | Morriss et al. | May 2017 | A1 |
20170143481 | Morriss et al. | May 2017 | A1 |
20170156723 | Keating et al. | Jun 2017 | A1 |
20170165057 | Morriss et al. | Jun 2017 | A9 |
20170189177 | Schweich et al. | Jul 2017 | A1 |
20170216025 | Nitzan et al. | Aug 2017 | A1 |
20170224479 | Seguin | Aug 2017 | A1 |
20170245850 | Call et al. | Aug 2017 | A1 |
20170258585 | Marquez et al. | Sep 2017 | A1 |
20170273788 | O'Carroll et al. | Sep 2017 | A1 |
20170273789 | Yaron et al. | Sep 2017 | A1 |
20170281341 | Lim et al. | Oct 2017 | A1 |
20170311937 | Bambury et al. | Nov 2017 | A1 |
20170348099 | Mendelson et al. | Dec 2017 | A1 |
20180021546 | McDermott et al. | Jan 2018 | A1 |
20180049873 | Manash et al. | Feb 2018 | A1 |
20180055628 | Patel et al. | Mar 2018 | A1 |
20180092763 | Dagan et al. | Apr 2018 | A1 |
20180110622 | Gregg et al. | Apr 2018 | A1 |
20180116790 | Ratz et al. | May 2018 | A1 |
20180133003 | Levi | May 2018 | A1 |
20180153690 | Spence | Jun 2018 | A1 |
20180177592 | Benichou et al. | Jun 2018 | A1 |
20180177594 | Patel | Jun 2018 | A1 |
20180206982 | Haivatov et al. | Jul 2018 | A1 |
20180206986 | Noe et al. | Jul 2018 | A1 |
20180206992 | Brown | Jul 2018 | A1 |
20180207395 | Bulman et al. | Jul 2018 | A1 |
20180214267 | Lally et al. | Aug 2018 | A1 |
20180214270 | Subramanian et al. | Aug 2018 | A1 |
20180221014 | Darabian | Aug 2018 | A1 |
20180228608 | Sheps et al. | Aug 2018 | A1 |
20180228610 | Lashinski et al. | Aug 2018 | A1 |
20180235443 | Smith et al. | Aug 2018 | A1 |
20180250126 | O'Connor et al. | Sep 2018 | A1 |
20180250132 | Ketai et al. | Sep 2018 | A1 |
20180263764 | Manash et al. | Sep 2018 | A1 |
20180280171 | Gloss et al. | Oct 2018 | A1 |
20180289473 | Rajagopal et al. | Oct 2018 | A1 |
20180289474 | Rajagopal et al. | Oct 2018 | A1 |
20180289478 | Quill | Oct 2018 | A1 |
20180289480 | D'Ambra et al. | Oct 2018 | A1 |
20180289485 | Rajagopal et al. | Oct 2018 | A1 |
20180296335 | Miyashiro | Oct 2018 | A1 |
20180296338 | Rabito et al. | Oct 2018 | A1 |
20180318079 | Patel et al. | Nov 2018 | A1 |
20180325665 | Gurovich et al. | Nov 2018 | A1 |
20180333259 | Dibie | Nov 2018 | A1 |
20180344303 | Bambury et al. | Dec 2018 | A1 |
20180344454 | Mauch et al. | Dec 2018 | A1 |
20180344459 | Spence et al. | Dec 2018 | A1 |
20180344971 | Suzuki et al. | Dec 2018 | A1 |
20180360600 | Zhuang et al. | Dec 2018 | A1 |
20180368830 | O'Carroll et al. | Dec 2018 | A1 |
20190000614 | Morriss et al. | Jan 2019 | A1 |
20190000615 | Tayeb et al. | Jan 2019 | A1 |
20190000625 | O'Carroll et al. | Jan 2019 | A1 |
20190008635 | Francis et al. | Jan 2019 | A1 |
20190008639 | Landon et al. | Jan 2019 | A1 |
20190008640 | Cooper et al. | Jan 2019 | A1 |
20190015205 | Rajagopal et al. | Jan 2019 | A1 |
20190021859 | O'Carrol et al. | Jan 2019 | A1 |
20190046315 | Gao et al. | Feb 2019 | A1 |
20190053894 | Levi et al. | Feb 2019 | A1 |
20190053895 | Levi | Feb 2019 | A1 |
20190053898 | Maimon et al. | Feb 2019 | A1 |
20190053899 | Levi | Feb 2019 | A1 |
20190053903 | Rohl et al. | Feb 2019 | A1 |
20190060068 | Cope et al. | Feb 2019 | A1 |
20190060069 | Maimon et al. | Feb 2019 | A1 |
20190060071 | Lane et al. | Feb 2019 | A1 |
20190076244 | Yohanan et al. | Mar 2019 | A1 |
20190076664 | Ollivier | Mar 2019 | A1 |
20190117392 | Quadri et al. | Apr 2019 | A1 |
20190133756 | Zhang et al. | May 2019 | A1 |
20190133757 | Zhang et al. | May 2019 | A1 |
20190142589 | Basude | May 2019 | A1 |
20190159770 | Rohl et al. | May 2019 | A1 |
20190160292 | Peichel et al. | May 2019 | A1 |
20190167425 | Reich et al. | Jun 2019 | A1 |
20190183649 | Allen et al. | Jun 2019 | A1 |
20190192288 | Levi et al. | Jun 2019 | A1 |
20190192294 | Spence et al. | Jun 2019 | A1 |
20190192296 | Schwartz et al. | Jun 2019 | A1 |
20190201191 | McLean et al. | Jul 2019 | A1 |
20190209311 | Zhang et al. | Jul 2019 | A1 |
20190209312 | Zhang et al. | Jul 2019 | A1 |
20190209313 | Zhang et al. | Jul 2019 | A1 |
20190209314 | Zhang et al. | Jul 2019 | A1 |
20190209315 | Zhang et al. | Jul 2019 | A1 |
20190209316 | Zhang et al. | Jul 2019 | A1 |
20190209317 | Zhang et al. | Jul 2019 | A1 |
20190209318 | Zhang et al. | Jul 2019 | A1 |
20190209320 | Drasler et al. | Jul 2019 | A1 |
20190231520 | Desrosiers et al. | Aug 2019 | A1 |
20190240023 | Spence et al. | Aug 2019 | A1 |
20190246916 | Kuraguntla et al. | Aug 2019 | A1 |
20190254816 | Anderson et al. | Aug 2019 | A1 |
20190261995 | Goldfarb et al. | Aug 2019 | A1 |
20190261996 | Goldfarb et al. | Aug 2019 | A1 |
20190261997 | Goldfarb et al. | Aug 2019 | A1 |
20190262129 | Cooper et al. | Aug 2019 | A1 |
20190282237 | Goldfarb et al. | Sep 2019 | A1 |
20190328518 | Neumann | Oct 2019 | A1 |
20190336282 | Christianson et al. | Nov 2019 | A1 |
20190343625 | Gharib et al. | Nov 2019 | A1 |
20190365530 | Hoang et al. | Dec 2019 | A1 |
20190374337 | Zamani et al. | Dec 2019 | A1 |
20190374342 | Gregg et al. | Dec 2019 | A1 |
20200000579 | Manash et al. | Jan 2020 | A1 |
20200000586 | Tian et al. | Jan 2020 | A1 |
20200008936 | Cheema et al. | Jan 2020 | A1 |
20200022811 | Griswold et al. | Jan 2020 | A1 |
20200054453 | Zerkowski et al. | Feb 2020 | A1 |
20200060813 | Nguyen et al. | Feb 2020 | A1 |
20200060820 | Ben-Zvi et al. | Feb 2020 | A1 |
20200078000 | Rajagopal et al. | Mar 2020 | A1 |
20200093601 | Neustadter | Mar 2020 | A1 |
20200107932 | Rabito et al. | Apr 2020 | A1 |
20200107933 | Oba | Apr 2020 | A1 |
20200113586 | Karasic et al. | Apr 2020 | A1 |
20200113685 | Miller et al. | Apr 2020 | A1 |
20200113696 | Ekvall et al. | Apr 2020 | A1 |
20200138575 | Tuval | May 2020 | A1 |
20200178977 | Coleman et al. | Jun 2020 | A1 |
20200188107 | Gloss et al. | Jun 2020 | A1 |
20200205800 | Gilmore et al. | Jul 2020 | A1 |
20200205969 | Hacohen | Jul 2020 | A1 |
20200205974 | Zerkowski et al. | Jul 2020 | A1 |
20200205975 | Khairkhahan | Jul 2020 | A1 |
20200205979 | O'Carroll et al. | Jul 2020 | A1 |
20200214708 | Sharma | Jul 2020 | A1 |
20200229806 | Goldfarb et al. | Jul 2020 | A1 |
20200229918 | Pham et al. | Jul 2020 | A1 |
20200275921 | Gilmore et al. | Sep 2020 | A1 |
20200276017 | Subramanian et al. | Sep 2020 | A1 |
20200297489 | Bishop et al. | Sep 2020 | A1 |
20200352705 | Heneghan et al. | Nov 2020 | A1 |
20200352706 | Campbell | Nov 2020 | A1 |
20200360139 | Hammer et al. | Nov 2020 | A1 |
20210022854 | Zhao et al. | Jan 2021 | A1 |
20210022860 | Lally et al. | Jan 2021 | A1 |
20210030536 | Kaleta | Feb 2021 | A1 |
20210121289 | Bruchman et al. | Apr 2021 | A1 |
20210128297 | Braido et al. | May 2021 | A1 |
20210145573 | Dasi et al. | May 2021 | A1 |
20210161688 | Shahriari | Jun 2021 | A1 |
20210177583 | Colavito et al. | Jun 2021 | A1 |
20210177584 | Levi et al. | Jun 2021 | A1 |
20210177587 | Braido | Jun 2021 | A1 |
20210228343 | Scheinblum et al. | Jul 2021 | A1 |
20220054261 | Argento et al. | Feb 2022 | A1 |
20230105492 | Argento et al. | Apr 2023 | A1 |
20230118748 | Argento | Apr 2023 | A1 |
20230165679 | Boyd et al. | Jun 2023 | A1 |
20230225861 | Argento et al. | Jul 2023 | A1 |
20240293217 | Cartledge et al. | Sep 2024 | A1 |
Number | Date | Country |
---|---|---|
2012261727 | Oct 2015 | AU |
2019246822 | Aug 2020 | AU |
2020227034 | Sep 2020 | AU |
PI0820603 | Jun 2020 | BR |
2979817 | Sep 2016 | CA |
2954826 | Oct 2019 | CA |
103764216 | Apr 2014 | CN |
103974670 | Aug 2014 | CN |
105358098 | Feb 2016 | CN |
107690323 | Feb 2018 | CN |
111110401 | May 2020 | CN |
108601655 | Jun 2020 | CN |
111265335 | Jun 2020 | CN |
111278389 | Jun 2020 | CN |
111329541 | Jun 2020 | CN |
19857887 | May 2005 | DE |
102014102650 | Sep 2015 | DE |
1105181 | Feb 2004 | EP |
1432369 | Feb 2008 | EP |
2374415 | Oct 2011 | EP |
2907479 | Aug 2015 | EP |
3037064 | Jun 2016 | EP |
3158975 | Apr 2017 | EP |
3342355 | Jul 2018 | EP |
3395296 | Oct 2018 | EP |
3406225 | Nov 2018 | EP |
3417831 | Dec 2018 | EP |
3476366 | May 2019 | EP |
3482718 | May 2019 | EP |
2637607 | Oct 2019 | EP |
3554424 | Oct 2019 | EP |
3244809 | Feb 2020 | EP |
3639792 | Apr 2020 | EP |
3417831 | May 2020 | EP |
3649963 | May 2020 | EP |
2072027 | Jun 2020 | EP |
3441045 | Jul 2020 | EP |
3672528 | Jul 2020 | EP |
3554423 | Aug 2020 | EP |
3107498 | Sep 2020 | EP |
3570782 | Sep 2020 | EP |
3700467 | Sep 2020 | EP |
3705090 | Sep 2020 | EP |
3782585 | Feb 2021 | EP |
H08131551 | May 1996 | JP |
2004154177 | Jun 2004 | JP |
2008018139 | Jan 2008 | JP |
2011506017 | Mar 2011 | JP |
2012531270 | Dec 2012 | JP |
2020515375 | May 2020 | JP |
2020517379 | Jun 2020 | JP |
2020520729 | Jul 2020 | JP |
6735294 | Aug 2020 | JP |
2020032237 | Mar 2020 | KR |
2020033349 | Mar 2020 | KR |
2020033350 | Mar 2020 | KR |
202027694 | Aug 2020 | TW |
WO2007007873 | Jan 2007 | WO |
WO2007081820 | Jul 2007 | WO |
WO2010141847 | Dec 2010 | WO |
WO2011025945 | Mar 2011 | WO |
WO2012087842 | Jun 2012 | WO |
WO2012145545 | Oct 2012 | WO |
WO2013190910 | Dec 2013 | WO |
WO2015127264 | Aug 2015 | WO |
WO2015173609 | Nov 2015 | WO |
WO2015195823 | Dec 2015 | WO |
WO2016052145 | Apr 2016 | WO |
WO2016117169 | Jul 2016 | WO |
WO2016183485 | Nov 2016 | WO |
WO2017121193 | Jul 2017 | WO |
WO-2017151566 | Sep 2017 | WO |
WO2017214098 | Dec 2017 | WO |
WO2018025260 | Feb 2018 | WO |
WO2018039561 | Mar 2018 | WO |
WO2018039589 | Mar 2018 | WO |
WO2018112429 | Jun 2018 | WO |
WO2018119304 | Jun 2018 | WO |
WO2018178966 | Oct 2018 | WO |
WO2018178967 | Oct 2018 | WO |
WO2018187390 | Oct 2018 | WO |
WO2018192197 | Oct 2018 | WO |
WO-2019010370 | Jan 2019 | WO |
WO2019036592 | Feb 2019 | WO |
WO2019062366 | Apr 2019 | WO |
WO2019081777 | May 2019 | WO |
WO2019102484 | May 2019 | WO |
WO-2019086958 | May 2019 | WO |
WO2019116369 | Jun 2019 | WO |
WO-2019118371 | Jun 2019 | WO |
WO2019135011 | Jul 2019 | WO |
WO2019135028 | Jul 2019 | WO |
WO2019144036 | Jul 2019 | WO |
WO2019147504 | Aug 2019 | WO |
WO2019147846 | Aug 2019 | WO |
WO2019154124 | Aug 2019 | WO |
WO2019164516 | Aug 2019 | WO |
WO2019195860 | Oct 2019 | WO |
WO2019209927 | Oct 2019 | WO |
WO2019222694 | Nov 2019 | WO |
WO2019241777 | Dec 2019 | WO |
WO2020051147 | Mar 2020 | WO |
WO2020051591 | Mar 2020 | WO |
WO2020072199 | Apr 2020 | WO |
WO2020072201 | Apr 2020 | WO |
WO2020073050 | Apr 2020 | WO |
WO2020082039 | Apr 2020 | WO |
WO2020123719 | Jun 2020 | WO |
WO2020157018 | Aug 2020 | WO |
WO2020163112 | Aug 2020 | WO |
WO2020210685 | Oct 2020 | WO |
WO2020236830 | Nov 2020 | WO |
WO2020247907 | Dec 2020 | WO |
WO2021028867 | Feb 2021 | WO |
WO2021034497 | Feb 2021 | WO |
Entry |
---|
Westaby et al.; Adult human valve dimensions and their surgical significance; The American Journal of Cardiology; 53(4); pp. 552-556; Feb. 1984. |
Argento et al.; U.S. Appl. No. 16/594,946 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Oct. 7, 2019. |
Argento et al.; U.S. Appl. No. 16/723,537 entitled “Prothetic cardiac valve devices, systems, and methods,” filed Dec. 20, 2019. |
Argento et al.; U.S. Appl. No. 16/824,576 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Mar. 19, 2020. |
PCT/US2019/47842 International Search Report dated Jan. 2, 2020. |
Argento et al.; U.S. Appl. No. 17/170,717 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Feb. 8, 2021. |
Argento et al.; U.S. Appl. No. 17/286,724 entitled “Adjustable medical device,” filed Apr. 19, 2021. |
Salahieh et al.; U.S. Appl. No. 17/543,555 entitled “Flared prosthetic cardiac valve delivery devices and systems,” filed Dec. 6, 2021. |
Yang et al.; U.S. Appl. No. 17/651,040 entitled “Anchor for prosthetic cardiac valve delivery devices and systems”. |
Salahieh.; U.S. Appl. No. 17/655,978 entitled “Anchor position verification for prosthetic cardiac valve devices,” filed Mar. 22, 2022. |
Saul; U.S. Appl. No. 17/773,193 entitled “Prosthetic cardiac valve delivery devices, systems, and methods,” filed Apr. 29, 2022. |
Argento et al.; U.S. Appl. No. 17/931,408 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Sep. 12, 2022. |
Adamek-Bowers et al.; U.S. Appl. No. 18/043,458 entitled “Prosthetic valve delivery system,” filed Feb. 28, 2023. |
Backus et al.; U.S. Appl. No. 18/004,609 entitled “Valve delivery system,” filed Jan. 6, 2023. |
Mulcahy et al.; U.S. Appl. No. 18/043,480 entitled “Prosthetic cardiac valve delivery devices, systems, and methods,” filed Feb. 28, 2023. |
Adamek-Bowers et al.; U.S. Appl. No. 18/043,499 entitled “Interface for prosthetic cardiac valve and delivery systems,” filed Feb. 28, 2023. |
Salahieh et al.; U.S. Appl. No. 18/043,519 entitled “Flared prosthetic cardiac valve delivery devices and systems,” filed Feb. 28, 2023. |
Scott et al.; U.S. Appl. No. 18/043,526 entitled “Access sheath for prosthetic cardiac valve delivery systems,” filed Feb. 28, 2023. |
Yang et al.; U.S. Appl. No. 18/043,542 entitled “Anchor for prosthetic cardiac valve devices,” filed Feb. 28, 2023. |
Argento et al.; U.S. Appl. No. 18/246,307 entitled “Systems, methods, and devices for expandable sensors,” filed Mar. 22, 2023. |
Argento et al.; U.S. Appl. No. 18/246,311 entitled “Prosthetic cardiac valve sensor devices, systems, and methods with imaging,” filed Mar. 22, 2023. |
Argento et al.; U.S. Appl. No. 18/185,330 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Mar. 16, 2023. |
Adamek-Bowers et al.; U.S. Appl. No. 18/255,763 entitled “Mitral valve implants,” filed Jun. 2, 2023. |
Schaefer; Large heart valves—small heart valves; ISMAAP; Oct. 19, 2015; 5 pages; retrieved from the internet (https://www.ismaap.org/condition-detail/large-heart-valves-small-heart-valves/) on Mar. 21, 2023. |
Argento et al.; U.S. Appl. No. 18/494,520 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Oct. 25, 2023. |
Mulcahy et al.; U.S. Appl. No. 18/573,816 entitled “Prosthetic cardiac valve delivery devices, systems, and methods,” filed Dec. 22, 2023. |
Boyd et al.; U.S. Appl. No. 18/688,735 entitled “Guide catheter for prosthetic cardiac valve delivery systems, ” filed Mar. 1, 2024. |
Adamek-Bowers et al.; U.S. Appl. No. 18/693,856 entitled “Tether delivery of cardiac valve,” filed Mar. 20, 2024. |
Yang et al.; U.S. Appl. No. 18/700,621 entitled “Cardiac valve prosthesis delivery system and methods of use,” filed Apr. 11, 2024. |
Argento et al.; U.S. Appl. No. 18/639,743 entitled “Prosthetic cardiac valve devices, systems and methods,” filed Apr. 18, 2024. |
Masterclass; Knit vs. Woven: Learn How to Identify the Two Fabric Types; Jun. 7, 2021; 13 pages; retrieved from the internet (https://www.masterclass.com/articles/knit-vs-woven-learn-how-to-identify-the-two-fabric-types) on Nov. 15, 2024. |
Number | Date | Country | |
---|---|---|---|
20200060852 A1 | Feb 2020 | US |
Number | Date | Country | |
---|---|---|---|
62720853 | Aug 2018 | US |